Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications

Care Management Institute, Kaiser Permanente, Oakland, CA 94612, USA.
The American journal of managed care (Impact Factor: 2.26). 10/2009; 15(10):e88-94.
Source: PubMed


To assess the effect of promoting a bundle of fixed doses of a generic statin and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), delivered with minimal outpatient visits, laboratory testing, and dosage titration, to people with diabetes, coronary artery disease (CAD), or both in a large integrated healthcare system.
Three-year observational study of 170,024 Kaiser Permanente members with diabetes, CAD, or both.
Using instrumental variable analysis, we assessed the impact of promoting the cardioprotective bundle on hospitalization rates for stroke and myocardial infarction (MI).
In 2004 and 2005, 47,268 of 170,024 individuals received "low exposure" (medication possession on 1 to 365 days). Their risk of hospitalization for MI or stroke in 2006 was lowered by 15 events per 1000 person-years (95% confidence interval [CI] = 1, 30), preventing events in 726 people. Furthermore, 21,292 of 170,024 individuals received "high exposure" (medication possession on 366 to 730 days). Their risk of hospitalization for MI or stroke was reduced by 26 events per 1000 person-years (95% CI = 17, 34), preventing events in 545 people.
A simplified method for bundling fixed doses of a generic statin and an ACEI/ARB was successfully implemented in a large, diverse population in an integrated healthcare delivery system, reducing the risk of hospitalization for MI and stroke.

12 Reads
  • Source
    • "To set the scene for the comparative analysis we briefly present how diabetes care is provided in the two healthcare systems. KP screens members for diabetes, and structured medication management and education programs are implemented in KP as part of diabetes care [16]. All persons newly diagnosed with diabetes are offered diabetes education, which includes diet counseling and smoking cessation programs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Self-management support is considered to be an essential part of diabetes care. However, the implementation of self-management support within healthcare settings has appeared to be challenging and there is increased interest in "real world" best practice examples to guide policy efforts. In order to explore how different approaches to diabetes care and differences in management structure influence the provision of SMS we selected two healthcare systems that have shown to be comparable in terms of budget, benefits and entitlements. We compared the extent of SMS provided and the self-management behaviors of people living with diabetes in Kaiser Permanente (KP) and the Danish Healthcare System (DHS). Self-administered questionnaires were used to collect data from a random sample of 2,536 individuals with DM from KP and the DHS in 2006-2007 to compare the level of SMS provided in the two systems and identify disparities associated with educational attainment. The response rates were 75 % in the DHS and 56 % in KP. After adjusting for gender, age, educational level, and HbA1c level, multiple linear regression analyses determined the level of SMS provided and identified disparities associated with educational attainment. Receipt of SMS varied substantially between the two systems. More people with diabetes in KP reported receiving all types of SMS and use of SMS tools compared to the DHS (p < .0001). Less than half of all respondents reported taking diabetes medication as prescribed and following national guidelines for exercise. Despite better SMS support in KP compared to the DHS, self-management remains an under-supported area of care for people receiving care for diabetes in the two health systems. Our study thereby suggests opportunity for improvements especially within the Danish healthcare system and systems adopting similar SMS support strategies.
    BMC Health Services Research 06/2012; 12(1):160. DOI:10.1186/1472-6963-12-160 · 1.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes and coronary heart disease (CHD) are two of the most prevalent medical illnesses in the US population and comorbid depression occurs in up to 20% of these patients. Guidelines for management of diabetes and CHD overlap for healthy lifestyle and disease-control recommendations. However, the majority of patients with these medical illnesses have been shown to have inadequate control of key risk factors such as blood pressure, LDL cholesterol, or blood sugar. Comorbid depression has been shown to adversely affect self-care of diabetes and CHD, and is associated with an increased risk of complications and mortality. Interventions that have improved quality and outcomes of depression care alone in patients with diabetes and CHD have not demonstrated benefits in self-care, improved disease control or morbidity and mortality. This paper describes the design and development of a new biopsychosocial intervention (TEAMcare) aimed at improving both medical disease control and depression in patients with poor control of diabetes and/or CHD who met the criteria for comorbid depression. A team approach is used with a nurse interventionist who receives weekly psychiatric and primary care physician caseload supervision in order to enhance treatment by the primary care physician. This intervention is being tested in an NIMH-funded randomized controlled trial in a large integrated health plan.
    Contemporary clinical trials 03/2010; 31(4):312-22. DOI:10.1016/j.cct.2010.03.009 · 1.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular diseases (CVD) account for one-third of annual global mortality. The aggregated benefits of concurrently controlling common CVD risk factors, such as dyslipidemia and hypertension, in people at overall risk for CVD is postulated to be more efficient than treating each individual risk factor to target. Administration of a polypill consisting of cholesterol-lowering (statins), antihypertensive, and antiplatelet agents together would simultaneously lower multiple risk factors, and applying such a population risk-reduction strategy would drastically reduce CVD incidence. This idea has generated much controversy and debate over the past decade. A few studies have emerged providing early evidence about the safety and efficacy of such a pill, and the results of ongoing and planned studies of outcome are eagerly anticipated. In this article, we review and interpret the existing evidence as well as explore the potential of a polypill for primary and secondary prevention of CVD.
    Annual Review of Public Health 03/2010; 32(1):23-38. DOI:10.1146/annurev-publhealth-031210-101214 · 6.47 Impact Factor
Show more


12 Reads
Available from